SRR23303745
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.500
- KRAS_SIGNALING_DN+0.400
- PANCREAS_BETA_CELLS+0.380
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.320
- HEDGEHOG_SIGNALING+0.310
- UV_RESPONSE_DN+0.150
- SPERMATOGENESIS+0.140
- APICAL_JUNCTION+0.110
- COAGULATION+0.080
- ANGIOGENESIS+0.050
Top 10 suppressed
- MYC_TARGETS_V2-0.700
- MYC_TARGETS_V1-0.640
- E2F_TARGETS-0.590
- MTORC1_SIGNALING-0.560
- G2M_CHECKPOINT-0.540
- UNFOLDED_PROTEIN_RESPONSE-0.540
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.490
- CHOLESTEROL_HOMEOSTASIS-0.480
- OXIDATIVE_PHOSPHORYLATION-0.480
- DNA_REPAIR-0.470
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR33346962 | — | — | 0.967 |
| 2 | d7bbb44a-3fe0-4455-99d0-90be213f2a31 | — | — | 0.928 |
| 3 | SRR658977 | GTEX | — | 0.924 |
| 4 | BS_CZ82ANWP | DNET | — | 0.923 |
| 5 | SRR1407134 | GTEX | — | 0.913 |
| 6 | SRR1336006 | GTEX | — | 0.912 |
| 7 | TCGA-44-A4SU-01A-11R-A24X-07 | — | cohortA1 | 0.909 |
| 8 | SRR1475257 | GTEX | — | 0.908 |
| 9 | SRR1353285 | GTEX | — | 0.908 |
| 10 | SRR1451964 | GTEX | — | 0.906 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.500 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.400 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.380 | Cobimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.320 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.310 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.150 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.110 | Inavolisib | — uncovered |
| COAGULATION | 0.080 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.050 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.040 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.040 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.010 | Inavolisib | — uncovered |